GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Cash Received from Insurance Activities

Sorrento Therapeutics (LTS:0L85) Cash Received from Insurance Activities


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Cash Received from Insurance Activities?

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Sorrento Therapeutics (LTS:0L85) Business Description

Industry
Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.